{"id":"cd1579","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Application site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PDE4 inhibition increases intracellular cAMP levels in immune and inflammatory cells, suppressing the production of pro-inflammatory cytokines and chemokines. This mechanism is intended to reduce skin inflammation and immune activation in inflammatory skin diseases. The selective PDE4 inhibition provides a targeted approach to modulating innate immune responses.","oneSentence":"CD1579 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production in immune cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:05:02.618Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atopic dermatitis"},{"name":"Psoriasis"}]},"trialDetails":[{"nctId":"NCT03034460","phase":"PHASE2","title":"Efficacy and Safety of CD5024 1% in Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2016-04-25","conditions":"Acne","enrollment":70},{"nctId":"NCT01688531","phase":"PHASE1","title":"A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2012-08","conditions":"Acne","enrollment":38},{"nctId":"NCT01880320","phase":"PHASE3","title":"Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2013-07","conditions":"Acne Vulgaris","enrollment":503},{"nctId":"NCT02073448","phase":"PHASE3","title":"Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2014-03","conditions":"Acne Vulgaris","enrollment":417},{"nctId":"NCT02073461","phase":"PHASE2","title":"Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris.","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2014-03","conditions":"Acne Vulgaris","enrollment":236}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Benzoyl Peroxide 2.5% Gel"],"phase":"phase_3","status":"active","brandName":"CD1579","genericName":"CD1579","companyName":"Galderma R&D","companyId":"galderma-r-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CD1579 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production in immune cells. Used for Atopic dermatitis, Psoriasis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}